Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News

This article was originally published in Scrip

Executive Summary

This past week in US regulatory, legislative, legal and political news affecting the biopharmaceutical industry included the unveiling at a White House summit of new actions and commitments from government agencies, including the National Institutes of Health and the FDA, and private-sector participants, including Pfizer Inc. and Roche AG unit Genentech Inc., aimed at speeding President Barack Obama's Precision Medicine Initiative forward; the US Senate's confirmation of Robert Califf as the new commissioner of the FDA; oral arguments at the US Supreme Court in a pair of consolidated lawsuits whose outcome could have broad implications for patent litigation and potentially change the way life sciences companies decide whether to launch a product at-risk; and the US Court of Appeals for the Federal Circuit setting April 4 to hear Apotex Inc.'s appeal in a lawsuit brought by Amgen Inc., which has been trying to delay the marketing of the biosimilars maker's version of Neulasta (pegfilgrastim); plus other Washington news

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064621

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel